Crowd sentiment on ORMP · 30d

Method · 0 mentions

Bullish 0%

Neutral 100%

Bearish 0%

Across 0 classified mentions in the last 30 days, crowd sentiment for ORMP sits roughly neutral, with 0% reading bullish against 0% bearish across the classified sample.

ORMP earnings

SEC EDGAR

Date Period EPS Revenue

31 Mar 2026 Q1 2026 $0.91 —

31 Dec 2025 FY 2025 $1.50 $2M

30 Sep 2025 Q3 2025 $1.13 $2M

30 Jun 2025 Q2 2025 $0.31 $2M

Reported figures & scheduled dates · SEC EDGAR filings

About ORMP

Oramed Pharmaceuticals reported that its phase 3 trial for an oral insulin capsule did not meet primary or secondary endpoints, leading to the expected discontinuation of clinical activities for type 2 diabetes. The company analyzed trial data and identified responsive patient subpopulations, subsequently submitting a new phase 3 trial protocol to the FDA. Oramed is also reviewing its pipeline and evaluating strategic opportunities. The company has limited experience in conducting clinical trials and faces various risks and uncertainties related to product development, regulatory approval, and commercialization.

Company

CEO Nadav Kidron

Founded 2006

Headquarters New York, NY, United States

Exchange NasdaqCM

Sector Healthcare

Class Equity

Mentions · 30d 0

Classified base n=0

Website oramed.com

Most-discussed this week

MSFT Microsoft GOOGL Alphabet NFLX Netflix NVDA NVIDIA